Redeye: Surgical Science Q3 2022 - Dissecting the company’s Q3 numbers

2022-11-11 07:29:00

Redeye updates its estimates following Surgical Science’s Q3 2022 report, which we judge featured solid sales growth and profitability. We believe that weak cash flow during the quarter could be a concern if it persists long-term.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking.